421 related articles for article (PubMed ID: 27370399)
21. Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition.
Zhang P; Sun S; Li N; Ho ASW; Kiang KMY; Zhang X; Cheng YS; Poon MW; Lee D; Pu JKS; Leung GKK
J Neurooncol; 2017 May; 132(3):393-400. PubMed ID: 28293765
[TBL] [Abstract][Full Text] [Related]
22. Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines.
Liu Y; Xu N; Liu B; Huang Y; Zeng H; Yang Z; He Z; Guo H
Oncotarget; 2016 Jul; 7(28):43835-43851. PubMed ID: 27270310
[TBL] [Abstract][Full Text] [Related]
23. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
25. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
26. HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Wang Z; Hu P; Tang F; Lian H; Chen X; Zhang Y; He X; Liu W; Xie C
Cancer Lett; 2016 Aug; 379(1):134-42. PubMed ID: 27267806
[TBL] [Abstract][Full Text] [Related]
27. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
28. FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation.
Xu K; Zhang Z; Pei H; Wang H; Li L; Xia Q
Oncol Rep; 2017 Apr; 37(4):2391-2397. PubMed ID: 28260024
[TBL] [Abstract][Full Text] [Related]
29. The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells.
Dong F; Eibach M; Bartsch JW; Dolga AM; Schlomann U; Conrad C; Schieber S; Schilling O; Biniossek ML; Culmsee C; Strik H; Koller G; Carl B; Nimsky C
Neuro Oncol; 2015 Nov; 17(11):1474-85. PubMed ID: 25825051
[TBL] [Abstract][Full Text] [Related]
30. A novel strategy to increase the therapeutic potency of GBM chemotherapy via altering parenchymal/cerebral spinal fluid clearance rate.
Umlauf BJ; Frampton G; Cooper A; Greene HF
J Control Release; 2023 Dec; 364():195-205. PubMed ID: 37865172
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
Kim EH; Lee JH; Oh Y; Koh I; Shim JK; Park J; Choi J; Yun M; Jeon JY; Huh YM; Chang JH; Kim SH; Kim KS; Cheong JH; Kim P; Kang SG
Neuro Oncol; 2017 Feb; 19(2):197-207. PubMed ID: 27571886
[TBL] [Abstract][Full Text] [Related]
32. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27650817
[TBL] [Abstract][Full Text] [Related]
33. Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Kushal S; Wang W; Vaikari VP; Kota R; Chen K; Yeh TS; Jhaveri N; Groshen SL; Olenyuk BZ; Chen TC; Hofman FM; Shih JC
Oncotarget; 2016 Mar; 7(12):13842-53. PubMed ID: 26871599
[TBL] [Abstract][Full Text] [Related]
34. Diterpenoid honatisine overcomes temozolomide resistance in glioblastoma by inducing mitonuclear protein imbalance through disruption of TFAM-mediated mtDNA transcription.
Li Z; Sai K; Ma G; Chen F; Xu X; Chen L; Wang S; Li W; Huang G; Cui P
Phytomedicine; 2024 Jun; 128():155328. PubMed ID: 38522316
[TBL] [Abstract][Full Text] [Related]
35. Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Weyhenmeyer BC; Noonan J; Würstle ML; Lincoln FA; Johnston G; Rehm M; Murphy BM
Oncotarget; 2016 Sep; 7(38):61295-61311. PubMed ID: 27494880
[TBL] [Abstract][Full Text] [Related]
36. Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
Liu YJ; Ma YC; Zhang WJ; Yang ZZ; Liang DS; Wu ZF; Qi XR
Oncotarget; 2017 Jun; 8(26):42495-42509. PubMed ID: 28477008
[TBL] [Abstract][Full Text] [Related]
37. Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition.
Matias D; Balça-Silva J; Dubois LG; Pontes B; Ferrer VP; Rosário L; do Carmo A; Echevarria-Lima J; Sarmento-Ribeiro AB; Lopes MC; Moura-Neto V
Cell Oncol (Dordr); 2017 Jun; 40(3):247-261. PubMed ID: 28401486
[TBL] [Abstract][Full Text] [Related]
38. Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.
Chiang IT; Liu YC; Liu HS; Ali AAA; Chou SY; Hsu TI; Hsu FT
Neurotherapeutics; 2022 Mar; 19(2):616-634. PubMed ID: 35267171
[TBL] [Abstract][Full Text] [Related]
39. Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.
Velpula KK; Guda MR; Sahu K; Tuszynski J; Asuthkar S; Bach SE; Lathia JD; Tsung AJ
Oncotarget; 2017 May; 8(22):35639-35655. PubMed ID: 28410193
[TBL] [Abstract][Full Text] [Related]
40. Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma.
Vartanian A; Agnihotri S; Wilson MR; Burrell KE; Tonge PD; Alamsahebpour A; Jalali S; Taccone MS; Mansouri S; Golbourn B; Aldape KD; Zadeh G
Oncotarget; 2016 Oct; 7(43):69518-69535. PubMed ID: 27588472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
